Have £2k to spend? 2 FTSE 100 dividend stocks for 2020 I’d buy to retire on

Royston Wild picks out two income heroes he’d stash in his shares portfolio for 2020.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Looking for top dividend stocks to load into your ISA for 2020? GlaxoSmithKline (LSE: GSK) is one I’d happily buy on the strength of its product pipeline, one which promises to deliver supreme profits growth through the 2020s and probably beyond.

The Footsie drug giant has around 40 medicines in the development stage in big growth areas like oncology and HIV, a pipeline that is constantly delivering a steady stream of future revenues drivers. And I reckon the business could prove to be a wise pick for 2020 in particular as a backdrop of intense geopolitical and macroeconomic tetchiness boosts demand for safe-haven sectors like pharmaceuticals.

A mix of this rush-to-safety buying and some strong trading releases, such as third-quarter numbers that showed product sales boomed 16% to £9.4bn, has helped Glaxo’s share price also rise 16% so far in the current year. A low forward P/E ratio of 14.4 times gives plenty of room for more strength in the New Year too.

One final thing: at current prices, Glaxo also boasts a bruising 4.6% dividend yield for 2020, created by City expectations of another 80p per share annual payout. But it’s not the only income hero that I’d buy for the year ahead as I reckon National Grid (LSE: GSK) should also attract no shortage of safe-haven buying.

Supercharge your income flows

With a cooling UK (and global) economy raising the likelihood of a rush of profit warnings next year, firms that supply essential services like water, sewage management, electricity and gas are worth their weight in gold. To illustrate this,  National Grid, which operates the country’s vast network of pylons and substations, has seen its share price jump 17% so far in 2019.

There is some regulatory uncertainty here as Labour threatens to nationalise key utilities, but the likely failure of the party to seize power after tomorrow’s general election means that this only major threat to National Grid’s long-term profitability will be taken off the table.

Illustrating the company’s quality as a solid earnings generator even in tough economic times, City forecasts suggest that the network operator will follow a predicted 33% bottom-line rise in the current fiscal year (to March 2020) with an additional 6% advance in the following period. And as you’d expect, this leads to expectations of further dividend growth too.

Last year’s 47.34p per share total dividend is anticipated to rise to 48.7p in the present period and then to 50.1p in financial 2021, estimates that yield a mighty 5.5% and 5.6% respectively. But this is not the only reason to celebrate National Grid at current prices as it also commands an undemanding forward P/E ratio of 15.1 times, one that fails to fully reflect its supreme defensive qualities and leaves much scope for share price gains in the new calendar year.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »